Skip to nav Skip to content

  • Grants

    • Investigation of NRF2-Dependent Metabolic Liabilities (R37 MERIT award)
      Sponsor: Nat Institutes of Health
      PI:DeNicola, G.
    • Imaging Acidosis and Immune Therapy in PDAC
      Sponsor: Nat Institutes of Health
      PI (Contact):Gillies, R.,PI (MPI):Pilon-Thomas, S.
    • Defining the Role of Metabolic Heterogeneity in Melanoma Dissemination and Therapy Escape
      Sponsor: Nat Institutes of Health
      PI:Smalley, I.
    • Pyridine Nucleotides: Missing Link between Aging and Lung Cancer
      Sponsor: Florida Biomedical Research Program (FBRP)
      PI:DeNicola, G.,CO-PI:Gomes, A.
    • Engineering Bispecific Nanobodies for Detection of Breast Cancer Nodal Metastasis
      Sponsor: US Army
      PI (Contact):Morse, D.
    • Impact of extracellular glutathione catabolism on triple-negative breast cancer
      Sponsor: Nat Institutes of Health
      PI:DeNicola, G.
    • Defining and targeting the immune-suppressive metabolic microenvironment of leptomeningeal melanoma metastases
      Sponsor: Nat Institutes of Health
      PI:Smalley, I.
    • Tumor-stroma metabolic crosstalk in melanoma brain metastases
      Sponsor: Melanoma Research Alliance (MRA)
      PI:Smalley, I.
    • Ecology and Evolution of Breast Carcinogenesis
      Sponsor: Nat Institutes of Health
      PI:Silva, A.
    • PET Probes for Senescence Detection in Brain
      Sponsor: Nat Institutes of Health
      PI:Morse, D.
    • Translational studies for targeted alpha-particle therapy for rare melanomas
      Sponsor: US Army
      PI:Morse, D.
    • Improving therapy for leptomeningeal Non-Hodgkin B cell lymphoma by targeting the metabolic tumor microenvironment
      Sponsor: Amer Cancer Society
      PI:Smalley, I.
    • Orexin receptor agonist discovery for development of colon cancer targeted alpha particle therapy
      Sponsor: Moffitt Cancer Center
      PI:Morse, D.,PI:Duckett, D.,PI:Ji, M.
    • SOW#02: A Phase 1, Multicenter, Open-Label, Dose Escalation, and Dose Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of DCSZ11 as a Monotherapy in Patients with Advanced or Metastatic Solid Tumors
      Sponsor: Imaging Endpoints
      PI:Raghunand, N.

  • Publications

    • Alhaddad H, Ospina OE, Khaled ML, Ren Y, Vallebuona E, Boozo MB, Forsyth PA, Pina Y, Macaulay R, Law V, Tsai KY, Cress WD, Fridley B, Smalley I. Spatial transcriptomics analysis identifies a tumor-promoting function of the meningeal stroma in melanoma leptomeningeal disease. Cell Rep Med. 2024 Jun.5(6):101606. Pubmedid: 38866016.
    • Ward NP, Yoon SJ, Flynn T, Sherwood AM, Olley MA, Madej J, DeNicola GM. Mitochondrial respiratory function is preserved under cysteine starvation via glutathione catabolism in NSCLC. Nat Commun. 2024 May.15(1):4244. Pubmedid: 38762605. Pmcid: PMC11102494.
    • Arias-Lorza AM, Costello JR, Hingorani SR, Von Hoff DD, Korn RL, Raghunand N. Magnetic resonance imaging of tumor response to stroma-modifying pegvorhyaluronidase alpha (PEGPH20) therapy in early-phase clinical trials. Sci Rep. 2024 May.14(1):11570. Pubmedid: 38773189. Pmcid: PMC11109088.
    • Maura F, Rajanna AR, Ziccheddu B, Poos AM, Derkach A, Maclachlan K, Durante M, Diamond B, Papadimitriou M, Davies F, Boyle EM, Walker B, Hultcrantz M, Silva A, Hampton O, Teer JK, Siegel EM, Bolli N, Jackson GH, Kaiser M, Pawlyn C, Cook G, Kazandjian D, Stein C, Chesi M, Bergsagel L, Mai EK, Goldschmidt H, Weisel KC, Fenk R, Raab MS, Van Rhee F, Usmani S, Shain KH, Weinhold N, Morgan G, Landgren O. Genomic Classification and Individualized Prognosis in Multiple Myeloma. J Clin Oncol. 2024 Apr.42(11):1229-1240. Pubmedid: 38194610. Pmcid: PMC11095887.
    • Jasani N, Xu X, Posorske B, Kim Y, Vera O, Tsai KY, DeNicola GM, Karreth FA. MAPK-mediated PHGDH induction is essential for melanoma formation and represents an actionable vulnerability. bioRxiv. 2024 Apr. Pubmedid: 38659816. Pmcid: PMC11042198.
    • Law V, Smalley I, Evernden BR, Baldwin M, Smalley KSM, Forsyth PA. Ex Vivo Culture of Circulating Tumor Cells in the Cerebral Spinal Fluid from Melanoma Patients to Study Melanoma-Associated Leptomeningeal Disease. J Vis Exp. 2024 Mar.(205). Pubmedid: 38619274.
    • Bishop RT, Miller AK, Froid M, Nerlakanti N, Li T, Frieling JS, Nasr MM, Nyman KJ, Sudalagunta PR, Canevarolo RR, Silva AS, Shain KH, Lynch CC, Basanta D. The bone ecosystem facilitates multiple myeloma relapse and the evolution of heterogeneous drug resistant disease. Nat Commun. 2024 Mar.15(1):2458. Pubmedid: 38503736. Pmcid: PMC10951361.
    • Wallace G, Kundalia R, Vallebuona E, Cao B, Kim Y, Forsyth P, Soyano A, Smalley I, Pina Y. Factors associated with overall survival in breast cancer patients with leptomeningeal disease (LMD): a single institutional retrospective review. Breast Cancer Res. 2024 Mar.26(1):55. Pubmedid: 38553702. Pmcid: PMC10979566.
    • Jeong D, Morse B, Polk SL, Chen DT, Li J, Hodul P, Centeno BA, Costello J, Jiang K, Machado S, El Naqa I, Farah PT, Huynh T, Raghunand N, Mok S, Dam A, Malafa M, Qayyum A, Fleming JB, Permuth JB. Pancreatic Cyst Size Measurement on Magnetic Resonance Imaging Compared to Pathology. Cancers (Basel). 2024 Jan.16(1). Pubmedid: 38201633. Pmcid: PMC10778543.
    • Smalley I, Boire A, Brastianos P, Kluger HM, Hernando-Monge E, Forsyth PA, Ahmed KA, Smalley KSM, Ferguson S, Davies MA, Glitza Oliva IC. Leptomeningeal disease in melanoma: An update on the developments in pathophysiology and clinical care. Pigment Cell Melanoma Res. 2024 Jan.37(1):51-67. Pubmedid: 37622466.
    • Eroglu Z, Chen YA, Smalley I, Li J, Markowitz JK, Brohl AS, Tetteh L, Taylor H, Sondak VK, Khushalani NI, Smalley KSM. Combined BRAF, MEK, and heat-shock protein 90 inhibition in advanced BRAF V600-mutant melanoma. Cancer. 2024 Jan.130(2):232-243. Pubmedid: 37776537.
    • Sebastian NT, Webb A, Shilo K, Robb R, Xu-Welliver M, Haglund K, Brownstein J, DeNicola GM, Shen C, Williams TM. A PI3K gene expression signature predicts for recurrence in early-stage non-small cell lung cancer treated with stereotactic body radiation therapy. Cancer. 2023 Dec.129(24):3971-3977. Pubmedid: 37560930.
    • Burger KL, Fernandez MR, Meads MB, Sudalagunta PR, Oliveira PS, Renatino Canevarolo R, Alugubelli RR, Tungsevik A, De Avila G, Silva M, Graeter AI, Dai H, Vincelette ND, Prabhu A, Magaletti D, Yang C, Li W, Kulkarni A, Hampton OA, Koomen JM, Roush WR, Monastyrskyi A, Berglund AE, Silva AS, Cleveland JL, Shain KH. CK1δ and CK1ε Signaling Sustains Mitochondrial Metabolism and Cell Survival in Multiple Myeloma. Cancer Res. 2023 Dec.83(23):3901-3919. Pubmedid: 37702657. Pmcid: PMC10690099.
    • Greenwood HE, Edwards RS, Tyrrell WE, Barber AR, Baark F, Tanc M, Khalil E, Falzone A, Ward NP, DeBlasi JM, Torrente L, Pearce DR, Firth G, Smith LM, Timmermand OV, Huebner A, George ME, Swanton C, Hynds RE, DeNicola GM, Witney TH. Imaging the master regulator of the antioxidant response in non-small cell lung cancer with positron emission tomography. bioRxiv. 2023 Dec. Pubmedid: 38168428. Pmcid: PMC10760199.
    • Khaled ML, Ren Y, Kundalia R, Alhaddad H, Chen Z, Wallace GC, Evernden B, Ospina OE, Hall M, Liu M, Darville LNF, Izumi V, Chen YA, Pilon-Thomas S, Stewart PA, Koomen JM, Corallo SA, Jain MD, Robinson TJ, Locke FL, Forsyth PA, Smalley I. Branched-chain keto acids promote an immune-suppressive and neurodegenerative microenvironment in leptomeningeal disease. bioRxiv. 2023 Dec. Pubmedid: 38187773. Pmcid: PMC10769272.
    • Alhaddad H, Ospina OE, Khaled ML, Ren Y, Forsyth P, Pina Y, Macaulay R, Law V, Tsai KY, Cress WD, Fridley B, Smalley I. Spatial transcriptomics analysis identifies a unique tumor-promoting function of the meningeal stroma in melanoma leptomeningeal disease. bioRxiv. 2023 Dec. Pubmedid: 38187574. Pmcid: PMC10769278.
    • Conger KO, Chidley C, Ozgurses ME, Zhao H, Kim Y, Semina SE, Burns P, Rawat V, Sheldon R, Ben-Sahra I, Frasor J, Sorger PK, DeNicola GM, Coloff JL. ASCT2 is the primary serine transporter in cancer cells. bioRxiv. 2023 Oct. Pubmedid: 37873453. Pmcid: PMC10592681.
    • Arias-Lorza AM, Costello JR, Hingorani SR, Von Hoff DD, Korn RL, Raghunand N. Tumor Response to Stroma-Modifying Therapy: Magnetic Resonance Imaging Findings in Early-Phase Clinical Trials of Pegvorhyaluronidase alpha (PEGPH20). Res Sq. 2023 Sep. Pubmedid: 37720027. Pmcid: PMC10503830.
    • Ravi H, Hawkins SH, Stringfield O, Pereira M, Chen DT, Enderling H, Michael Yu HH, Arrington JA, Sahebjam S, Raghunand N. Rules-based Volumetric Segmentation of Multiparametric MRI for Response Assessment in Recurrent High-Grade Glioma. Res Sq. 2023 Sep. Pubmedid: 37790451. Pmcid: PMC10543497.
    • Ward NP. Cys-regulation: oxidized CHK1 controls cross-compartment circuit of chemoresistance. Trends Cancer. 2023 Sep.9(9):700-702. Pubmedid: 37532649.
    • Rawat V, DeLear P, Prashanth P, Ozgurses ME, Tebeje A, Burns PA, Conger KO, Solís C, Hasnain Y, Novikova A, Endress JE, González-Sánchez P, Dong W, Stephanopoulos G, DeNicola GM, Harris IS, Sept D, Mason FM, Coloff JL. Drug screening in human physiologic medium identifies uric acid as an inhibitor of rigosertib efficacy. bioRxiv. 2023 Jul. Pubmedid: 37546939. Pmcid: PMC10402161.
    • DeBlasi JM, Falzone A, Caldwell S, Prieto-Farigua N, Prigge JR, Schmidt EE, Chio IIC, Karreth FA, DeNicola GM. Distinct Nrf2 Signaling Thresholds Mediate Lung Tumor Initiation and Progression. Cancer Res. 2023 Jun.83(12):1953-1967. Pubmedid: 37062029. Pmcid: PMC10267679.